Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 27853644)

Published in Oncoimmunology on September 09, 2016


Patricia Kleinpeter1, Laetitia Fend2, Christine Thioudellet1, Michel Geist1, Nathalie Sfrontato1, Véronique Koerper1, Catherine Fahrner1, Doris Schmitt1, Murielle Gantzer1, Christelle Remy-Ziller1, Renée Brandely1, Dominique Villeval1, Karola Rittner1, Nathalie Silvestre1, Philippe Erbs1, Laurence Zitvogel3, Eric Quéméneur1, Xavier Préville1, Jean-Baptiste Marchand1

Author Affiliations

1: Transgene S.A. , Illkirch-Graffenstaden, France.
2: Transgene S.A., Illkirch-Graffenstaden, France; Institut Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
3: Institut Gustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM U1015, GRCC, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1418, GRCC, Villejuif, France; University of Paris Sud XI, Kremlin Bicêtre, France; Department of Immuno-Oncology, GRCC, Villejuif, France.

Associated clinical trials:

TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | NCT02254772

Articles cited by this

In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol (1985) 5.77

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20

Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J Virol (1986) 3.88

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med (2014) 3.62

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95

In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res (2000) 1.73

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin Cancer Res (2015) 1.61

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 1.55

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther (2014) 1.40

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29

Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24

Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A (2009) 1.19

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther (2011) 1.16

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther (2008) 1.12

Oncolytic Poxviruses. Annu Rev Virol (2014) 0.96

Immunoglobulin free light chain dimers in human diseases. ScientificWorldJournal (2011) 0.90

Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. MAbs (2013) 0.86

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res (2013) 0.84

Oncolytic vaccinia virus: a silver bullet? Expert Rev Vaccines (2010) 0.83

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther (2002) 0.79

Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther (2000) 0.79

Articles by these authors

Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83